End-of-day quote
Dhaka S.E.
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
15.6
BDT
|
-2.50%
|
|
-3.11%
|
-27.78%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,990
|
2,498
|
2,689
|
3,290
|
2,948
|
Enterprise Value (EV)
1 |
2,696
|
2,304
|
2,461
|
3,127
|
2,829
|
P/E ratio
|
20.1
x
|
21
x
|
22.4
x
|
32.2
x
|
89.1
x
|
Yield
|
2.61%
|
2.73%
|
2.54%
|
1.24%
|
0.46%
|
Capitalization / Revenue
|
4.08
x
|
3.27
x
|
3.36
x
|
4.22
x
|
4.11
x
|
EV / Revenue
|
3.68
x
|
3.02
x
|
3.08
x
|
4.02
x
|
3.95
x
|
EV / EBITDA
|
13.5
x
|
11
x
|
11.9
x
|
17.9
x
|
26.4
x
|
EV / FCF
|
-44.7
x
|
-39.2
x
|
46.2
x
|
-64.6
x
|
-100
x
|
FCF Yield
|
-2.24%
|
-2.55%
|
2.16%
|
-1.55%
|
-1%
|
Price to Book
|
1.4
x
|
1.14
x
|
1.18
x
|
1.41
x
|
1.26
x
|
Nbr of stocks (in thousands)
|
136,500
|
136,500
|
136,500
|
136,500
|
136,500
|
Reference price
2 |
21.90
|
18.30
|
19.70
|
24.10
|
21.60
|
Announcement Date
|
11/4/19
|
10/27/20
|
12/7/21
|
12/11/22
|
12/7/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
685.2
|
732.5
|
763.3
|
799.2
|
778.7
|
716.9
|
EBITDA
1 |
192.7
|
200.2
|
208.6
|
207.4
|
174.3
|
107.3
|
EBIT
1 |
140.7
|
142.8
|
139.9
|
142.1
|
111.8
|
44.78
|
Operating Margin
|
20.53%
|
19.5%
|
18.33%
|
17.78%
|
14.35%
|
6.25%
|
Earnings before Tax (EBT)
1 |
143.9
|
157.3
|
159.1
|
151.3
|
116.7
|
50.36
|
Net income
1 |
92.99
|
143.3
|
118.9
|
119.9
|
102.3
|
33.08
|
Net margin
|
13.57%
|
19.57%
|
15.58%
|
15%
|
13.13%
|
4.61%
|
EPS
2 |
0.8857
|
1.091
|
0.8714
|
0.8780
|
0.7491
|
0.2423
|
Free Cash Flow
1 |
76.04
|
-60.27
|
-58.77
|
53.24
|
-48.45
|
-28.2
|
FCF margin
|
11.1%
|
-8.23%
|
-7.7%
|
6.66%
|
-6.22%
|
-3.93%
|
FCF Conversion (EBITDA)
|
39.46%
|
-
|
-
|
25.67%
|
-
|
-
|
FCF Conversion (Net income)
|
81.77%
|
-
|
-
|
44.42%
|
-
|
-
|
Dividend per Share
|
-
|
0.5714
|
0.5000
|
0.5000
|
0.3000
|
0.1000
|
Announcement Date
|
8/8/18
|
11/4/19
|
10/27/20
|
12/7/21
|
12/11/22
|
12/7/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
36.3
|
294
|
194
|
228
|
162
|
120
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
76
|
-60.3
|
-58.8
|
53.2
|
-48.4
|
-28.2
|
ROE (net income / shareholders' equity)
|
5.54%
|
7.46%
|
5.49%
|
5.36%
|
4.45%
|
1.42%
|
ROA (Net income/ Total Assets)
|
4.46%
|
4.15%
|
3.68%
|
3.62%
|
2.8%
|
1.11%
|
Assets
1 |
2,086
|
3,455
|
3,236
|
3,309
|
3,654
|
2,983
|
Book Value Per Share
2 |
16.30
|
15.60
|
16.10
|
16.60
|
17.00
|
17.10
|
Cash Flow per Share
2 |
0.4800
|
0.3100
|
0.2700
|
0.4300
|
0.2700
|
0.2100
|
Capex
1 |
169
|
205
|
172
|
77.2
|
178
|
86.8
|
Capex / Sales
|
24.64%
|
28.03%
|
22.5%
|
9.66%
|
22.81%
|
12.11%
|
Announcement Date
|
8/8/18
|
11/4/19
|
10/27/20
|
12/7/21
|
12/11/22
|
12/7/23
|
|
1st Jan change
|
Capi.
|
---|
| -27.78% | 18.1M | | +62.66% | 854B | | +40.42% | 636B | | -4.37% | 361B | | +17.16% | 324B | | +9.87% | 301B | | +15.66% | 247B | | +17.90% | 228B | | +14.86% | 177B | | +0.45% | 164B |
Other Pharmaceuticals
|